Drugs / PENNVAX-B
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01082692 | Jan 2011 → Aug 2012 | HIV infectious disease | Inovio Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00991354 | Nov 2009 → Feb 2011 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00775424 | Sep 2008 → Jun 2010 | HIV infectious disease | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT00528489 | Oct 2007 → Jan 2010 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PENNVAX-B | “A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX™-B (Gag, Pol, Env) Vaccine, With or Without IL-12 DNA Plasmid, Delivered Via Electroporation in...” NCT00991354 ↗5“The purpose of this study is to determine the safety and tolerability of the DNA plasmid vaccine, PENNVAX-B when administered alone, or with IL-12 or IL-15 DNA adjuvants.” NCT00528489 ↗ |
| Modality | Vaccine | “DNA vaccine containing the HIV genes Gag, Pol, and Env” NCT00528489 ↗ |
| Route | Other | “PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6” NCT00528489 ↗ |